TRAVATAN Drug Patent Profile

Which patents cover Travatan, and when can generic versions of Travatan launch?

Travatan is a drug marketed by Alcon Pharms Ltd and Sandoz and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TRAVATAN is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travatan

A generic version of TRAVATAN was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVATAN

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	53
Patent Applications:	4,008
Drug Prices:	Drug price information for TRAVATAN
Drug Sales Revenues:	Drug sales revenues for TRAVATAN
DailyMed Link:	TRAVATAN at DailyMed

See drug prices for TRAVATAN

Recent Clinical Trials for TRAVATAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Hong Kong	N/A
Laboratorios Sophia S.A de C.V.	Phase 1
Novartis Pharmaceuticals	Phase 4

See all TRAVATAN clinical trials

Paragraph IV (Patent) Challenges for TRAVATAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRAVATAN	Ophthalmic Solution	travoprost	0.004%	021257	1	2008-11-28

US Patents and Regulatory Information for TRAVATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001		DISCN	Yes	No
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y

Expired US Patents for TRAVATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001

EU/EMA Drug Approvals for TRAVATAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for TRAVATAN

See the table below for patents covering TRAVATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	4822099
China	1146423
European Patent Office	0639563	Utilisation de l' ester isopropylique de fluprostenol pour la fabrication d'un médicament pour le traitement du glaucome et de l'hypertension oculaire (Use of fluprostenol isopropyl ester for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension)
Australia	704670
Austria	285795

Supplementary Protection Certificates for TRAVATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	CA 2012 00030	Denmark
1920764	C300540	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
1920764	92058	Luxembourg		92058, EXPIRES: 20161127
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1920764	C01920764/01	Switzerland		PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002

TRAVATAN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Travatan Z

Introduction to Travatan Z

Travatan Z is a brand-name prescription drug containing the active ingredient travoprost, used to treat increased eye pressure caused by ocular hypertension or open-angle glaucoma. It is part of the prostaglandin analogs class of medications, which are widely used in the treatment of these conditions.

Market Position and Competition

Travatan Z operates in a competitive market dominated by prostaglandin analogs. Other notable drugs in this class include latanoprost (Xalatan), which also competes for market share. The introduction of generic alternatives, such as the generic formulation of travoprost by Glenmark Pharmaceuticals, has further intensified the competition. This generic version is bioequivalent and therapeutically equivalent to Travatan Z, potentially impacting its market share and pricing[1].

Sales and Revenue

Despite the competitive landscape, Travatan Z has maintained a significant presence in the market. According to IQVIA sales data, Travatan Z achieved annual sales of approximately $66.2 million for the 12-month period ending September 2024. This figure indicates a stable revenue stream for the drug[1].

Pricing and Cost Considerations

The cost of Travatan Z is a critical factor in its market dynamics. As a brand-name drug, Travatan Z is generally more expensive than its generic counterparts. The introduction of generic travoprost is expected to offer a more affordable option for patients, potentially affecting the sales of Travatan Z.

• Brand-Name vs. Generic: The higher cost of Travatan Z compared to generic alternatives could lead to a shift in patient preferences towards more affordable options[1].
• Insurance and Mail-Order Pharmacies: The financial burden of Travatan Z can be mitigated through insurance coverage and mail-order pharmacy services. Some Medicare plans may help cover the cost, and mail-order pharmacies can provide a 90-day supply, reducing the financial burden on patients[1].

Manufacturer and Distribution

Novartis, the manufacturer of Travatan Z, plays a significant role in its market dynamics.

• Financial Performance: Novartis has reported strong financial performance in recent years, with core operating income and net sales increasing. However, integration costs and other exceptional charges related to acquisitions, such as Alcon, have impacted their overall financials[2][5].

Market Trends and Future Outlook

The ophthalmic drug market is evolving, with several trends affecting Travatan Z.

• Generic Competition: The launch of generic travoprost by Glenmark is expected to increase competition and potentially reduce the market share of Travatan Z. This trend may lead to price adjustments and marketing strategies to retain market position[1].
• Patient Preferences: Patients are increasingly seeking affordable and effective treatments. The availability of generic options may shift patient preferences, influencing the financial trajectory of Travatan Z[1].

Financial Trajectory

The financial trajectory of Travatan Z is influenced by several factors:

• Revenue Stability: Despite competition, Travatan Z has maintained significant annual sales, indicating a stable revenue stream[1].
• Cost and Pricing: The introduction of generic alternatives is likely to impact pricing strategies. Travatan Z may need to adjust its pricing to remain competitive[1].
• Manufacturer's Financial Health: Novartis's overall financial health, including its core operating income and net sales, will continue to influence the investment and marketing efforts for Travatan Z[2][5].

Impact of Generic Competition

Generic competition is a significant factor in the financial trajectory of Travatan Z. The entry of generic travoprost into the market is expected to increase price pressure and potentially reduce the market share of the brand-name drug.

"The launch of generic travoprost by Glenmark is expected to increase competition and potentially reduce the market share of Travatan Z. This trend may lead to price adjustments and marketing strategies to retain market position."[1]

Ophthalmic Drugs Market Growth

The ophthalmic drugs market, which includes Travatan Z, is projected to grow significantly. The market size was valued at USD 32.9 billion in 2021 and is expected to reach USD 62.55 billion by 2030, growing at a CAGR of 7.4%[4].

Regional Market Dynamics

The Asia-Pacific region is expected to grow at a CAGR of 5.65% over the forecast period, driven by a sizable patient pool, high illness prevalence, and the rise of local businesses. This region has the largest patient population but the lowest treatment rate, which is expected to drive market growth[4].

Strategic Actions by Manufacturers

Manufacturers are taking strategic actions to foster regional expansion. For instance, Otsuka Pharmaceutical Co., Ltd. and Senju Pharmaceutical Co., Ltd. announced the release of AILAMIDE in June 2020 as a combined ophthalmic solution for the treatment of glaucoma and ocular hypertension[4].

Financial Performance of Novartis

Novartis's financial performance is crucial for the continued success of Travatan Z. In recent years, Novartis has delivered mid single-digit sales growth, margin expansion, and advancements in its robust pipeline. However, the company has faced challenges such as price erosion and the negative impact of generic competition[5].

Key Takeaways

• Market Competition: Travatan Z faces competition from generic alternatives and other prostaglandin analogs.
• Pricing and Cost: The drug is more expensive than generic options, but mail-order pharmacies and insurance can mitigate costs.
• Effectiveness: Travatan Z is effective in reducing intraocular pressure (IOP), with clinical outcomes comparable to other treatments.
• Side Effects: Common side effects include eye redness and changes in iris pigmentation.
• Financial Performance: The drug maintains significant annual sales, but faces pricing pressure from generics.

FAQs

1. What is Travatan Z used for? Travatan Z is used to treat increased eye pressure caused by ocular hypertension or open-angle glaucoma.

2. Who manufactures Travatan Z? Travatan Z is manufactured by Novartis.

3. How does generic competition affect Travatan Z? The introduction of generic travoprost is expected to increase competition, potentially reducing the market share and pricing of Travatan Z.

4. What are the common side effects of Travatan Z? Common side effects include eye redness and changes in iris pigmentation.

5. How does the cost of Travatan Z compare to its generic alternatives? Travatan Z is generally more expensive than its generic counterparts, but costs can be mitigated through insurance coverage and mail-order pharmacy services.

Sources

1. DrugPatentWatch - TRAVATAN Z Drug Patent Profile
2. Novartis - Q4 and FY 2019 Condensed Financial Report
3. DrugBank Blog - Investment Trends in Pharmaceutical Research
4. StraitsResearch - Ophthalmic Drugs Market Size to Grow at a CAGR of 7.4% by 2030
5. Novartis - Financial Results Q4 2021 – English